EXACT SCIENCES CORP DEFA14A Filing

From the Filing

0001193125-25-300474.txt : 20251126 0001193125-25-300474.hdr.sgml : 20251126 20251126160104 ACCESSION NUMBER: 0001193125-25-300474 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20251126 DATE AS OF CHANGE: 20251126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXACT SCIENCES CORP CENTRAL INDEX KEY: 0001124140 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 200478229 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35092 FILM NUMBER: 251529955 BUSINESS ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 BUSINESS PHONE: 608-284-5700 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 FORMER COMPANY: FORMER CONFORMED NAME: EXACT CORP DATE OF NAME CHANGE: 20000919 DEFA14A 1 d935160ddefa14a.htm DEFA14A DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under §240.14a-12 EXACT SCIENCES CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 The following set of Frequently Asked Questions was made available to employees of Exact Sciences Corporation on November 26, 2025. This FAQ provides answers to common questions about the planned acquisition of Exact Sciences by Abbott. We will continue to update this document as more details become available. Table of Contents: 1. About the Abbott-Exact Sciences Combination • What is happening? • Why is this happening? • Why now? • Who is Abbott? • What does Abbott see in Exact Sciences? • What is the timeline? 2. Compensation & Benefits • Will there be changes to jobs, compensation, or benefits now? • Will I receive a 401(k) match this year? • How will Exact Sciences stock within the Exact Sciences 401(k) plan be treated? • Will I receive a bonus for 2025? • What will happen with my accrued but unused Vacation and/or Paid Sick and Safe Time benefits upon close? • How will an employee’s years of service with Exact Sciences be treated after close? • If an employee has an upcoming leave approved prior to close, will the leave still be approved after the close? If paid disability or parental leave benefits are available for the leave prior to close, will those same benefits be available for the approved leave after close? 3. Equity & Stock Programs • What happens to my outstanding equity (company stock)? • What will happen with the Employee Stock Purchase Program? • Can I buy or sell Exact Sciences stock between now and close? 4. Jobs, Severance & Company Culture • Will there be layoffs? • Will severance be provided to an Exact Sciences employee who experiences a role elimination due to this combination? • My role is being eliminated before close. Will my end date or severance benefits change? • What does this mean for Exact Sciences’ mission and culture? 5. Staying Informed • How will employees be kept informed? 1. About the Abbott-Exact Sciences Combination What is happening? Exact Sciences has agreed to be acquired by Abbott, a global healthcare leader. The combination is expected to close in the second quarter of 2026. Until then